Affiliations: [a] Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands
| [b] Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
Correspondence to: Prof. Bastiaan R. Bloem, MD, PhD, Department of Neurology, Radboud University Medical Center; Donders Institute for Brain, Cognition and Behavior; PO Box 9101 (947), 6500 HB Nijmegen, The Netherlands. Tel.: +31 0243615202; Fax: +31 24 3541122;E-mail: email@example.com.
Abstract: We present a 48-year-old woman with Parkinson’s disease in whom carbidopa was added to Mucuna pruriens, resulting in marked motor improvement (documented on video and using MDS-UPDRS motor scores). This case report shows that adding a dopa-decarboxylase inhibitor (DDCI) to Mucuna pruriens could fit well in a personalized approach for patients who are reluctant to start levodopa. Meanwhile, larger trials with a longer follow-up are needed to establish the true effects and tolerability of Mucuna pruriens plus a DDCI.
Keywords: Dopa-decarboxylase inhibitor, Mucuna pruriens, Parkinson’s disease, personalized medicine